Dr Siegel on the Current and Future Role of Mezigdomide in Multiple Myeloma

"As much as we have improved outcomes for patients with myeloma, there’s still a need for further improvement. We have every reason to [believe] that we’re continuing on that path, not just with mezigdomide, but with novel CAR T-cell therapies, new T-cell engagers, and all kinds of developments that [will allow] our patients to get better care, [achieve] better outcomes, and have better quality of life."

David Samuel Dicapua Siegel, MD, chief, Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, discusses the current and future role for mezigdomide (CC-92480) in the multiple myeloma treatment paradigm, and how this may evolve alongside the development of novel combinatorial approaches.

Preliminary findings from the phase 1/2 CA057-003 trial (NCT05372354) demonstrated clinical activity and safety with 3 novel, all-oral, mezigdomide (CC-92480)-based triplet regimens for heavily pretreated patients with relapsed/refractory multiple myeloma. These results provide a strong rationale for further exploration of mezigdomide in combination with tazemetostat (Tazverik) and other novel agents, Siegel states. He adds that the results have bolstered enthusiasm for advancing mezigdomide combinations and incorporating the agent as a cornerstone in future myeloma management.

Mezigdomide, a thalidomide derivative, is poised to become a staple in multiple myeloma management, akin to its predecessors lenalidomide (Revlimid) and pomalidomide (Pomalyst), Siegel continues. The drug shows potential for synergy with CAR T-cell therapies, T-cell engagers, proteasome inhibitors, and other emerging agents, he notes. Given its versatility and efficacy, mezigdomide is likely to maintain relevance in the evolving treatment landscape over the next decade, even as newer therapies replace other standard treatment options, Siegel emphasizes.

Although outcomes have improved for patients with multiple myeloma, there is still a substantial need for further advancement. Continued innovation with agents like mezigdomide, alongside novel CAR T-cell therapies and bispecific T-cell engagers, is expected to improve patient outcomes, access to effective care, and quality of life, Siegel concludes.